Check out Scrip’s annual ranking of Asia Pacific biopharma companies for 2024!
World View
Approximately 25% of active drug development originates from China, with a focus on biologics, cell therapies, and cancer R&D. Despite strong interest from multinational pharmaceutical companies, a financing crunch in the startup space is impacting China's biotech sector.
• By
Industry support for a new regional regulator for Latin America and the Caribbean is cautious and experts warn that it could harm competitiveness of the region.
• By
The emergence of China from API manufacturer to an innovation leader, fuelled by domestic investments and home-grown talent, has been one of the most remarkable trends of the last decade.
• By
An over-reliance on out-licensing as a business model may restrict the healthy growth of South Korean biopharma firms over the longer term, a Citeline executive told a recent symposium in Seoul.
• By
In the year since the Association of the British Pharmaceutical Industry raised the alarm about drastically dwindling clinical trial recruitment numbers in the UK, the country has taken a number of steps to try to turn things around.
The Asia 100 ranking is based on Citeline’s analysis of fiscal year 2022 prescription sales data. For more information contact: Ian.Haydock@citeline.com.
See more content from Scrip Asia 100.